Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES（2022）
Key words
preexisting resistance, primary integrase strand transfer inhibitor, bictegravir, emtricitabine, tenofovir alafenamide, DNA genotyping, virologic suppression
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined